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Hereditary angio-oedema is a rare autosomal dominant disease characterized by recurrent attacks of
subcutaneous oedema and caused by a deﬁciency of the plasma protein C1 inhibitor. Hereditary angio-
oedema attacks carry a high risk of morbidity or even mortality. In literature, there are only a few
publications on the treatment and follow-up of paediatric patients. We report the case of a 14-year-old
male with known hereditary angio-oedema since the age of six years, revealed by a recurrent acute
abdominal pain and oedema in subcutaneous tissues of extremities and face, and he was admitted once
for sub mucosal oedema of larynx with suffocation, treated by fresh-frozen plasma with favourable
outcome. Danazol was used for long-term prophylaxis. Clinical course improved over a follow-up of
12 months.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Hereditary angio-oedema (HAE) results from the deﬁciency of
C1-esterase inhibitor (C1-INH). It is caused by the mutation of the
C1 inhibitor gene, located in the 1, 2-q13 subregion of human
chromosome 11. Two major phenotypes of HAE have been
described. The classic type or type I is found in 85% of the patients
with HAE and it is characterized by low C1-INH antigenic and
functional levels. The other 15% of the patients have type II and
have normal serum levels of C1-INH, but the C1-INH protein is non-
functional. Even today, HAE remains a severe disease. In fact, if not
treated adequately the acute attacks of HAE can be life threatening,
especially in case of involvement of the upper airways.
2. Case report
A 14 year-old-male with known HAE type I since the age of six
years presented to our paediatric unit on the 13th January 2009 for
tachypnea and face swelling. On examination, her temperature
was 37 C, pulse rate was 120 beats per minute, respiratory rate
was 30 cycles per minute, blood pressure was 110/60 mmHg, and
arterial oxygen saturation was 85% on ambient air and 98% on 30%
inspired oxygen. His facial examination was remarkable for facial
swelling. His pulmonary examination showed only tachypnea. A
ﬁberoptic examination showed important laryngeal oedema. The: þ216 73 460 678.
mami).
rved.remaining physical examination was normal. Laboratory studies
showed a C1-INH level of 85 mg/L. His chest radiographic was
unremarkable. He was treated with corticosteroids, epinephrine
nebulized and fresh-frozen plasma with improvement of
symptoms. He had no other episodes of respiratory distress. He
was discharged on the fourth day without complications. Looking
for severity of acute oedematous attack and history of recurrent
abdominal pain, our patient received a long-term drug prophylaxis
with danazol 200 mg/day. Clinical course improved without
recurrence of oedematous attacks over 12-month follow-up. C1-
INH level at 12-month follow-up was 250 mg/L. In order to taper
the cumulative dose, the dosage interval was increased to 2 days
after 6 months of clinical remission. No adverse effect was
potentially related to long-term prophylaxis with danazol. The
bone age, skeletal growth, and weight development were normal.3. Discussion
HAE is a raredisease in childhood. C1 inhibitordeﬁciency leads to
recurrent angio-oedemathat canbe life threateningespeciallywhen
the larynx is involved.1,2 In undiagnosed cases, themortality of acute
oedematous attacks is still high. Then, it is imperative that diagnosis
of HAE be established early and correctly. The prevalence of HAE is
not well known. It has been estimated to range from 1:10,000 to
1:150,000. According to literature, 85% of HAE patients suffer from
type I disease. In general, initial clinical manifestations of HAE
appear before 6 years of age.3 In our case report, onset of diseasewas
at 6 years of age. Severity of HAE manifestations shows substantial
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that eleven out of the 26 children followed up had frequent and
severe attacks. Most precipitation factors of HAE attacks are
mechanical trauma and upper airways infection. In children,
oedema of the extremities is the dominant manifestation. Abdom-
inal attacks and laryngeal oedema are the most frequent severe
manifestation of HAE, witch should be considered as real
emergencies.5,6 The treatment of HAE consists of long-term
prophylaxis, short-term prophylaxis, and management of acute
attacks.7,8 In life-threatening HAE attacks, the most adequate
therapy is the intravenous administration of C1-INH concentrate.9,10
Nevertheless, in our case report, therapy with fresh-frozen plasma
was also effective. In paediatric population, anti-ﬁbrinolytic agents
are the ﬁrst choice for long-term prophylaxis.7,11 In adult's patients,
danazol has demonstrated its efﬁcacy by increasing serum
complement parameters signiﬁcantly and reducing the frequency
and severity of clinical manifestations.12 Because of the mechanism
of action of danazol has not yet been elucidated and regarding for its
potential adverse effects, experience use in paediatric population
has been limited in patients with idiopathic thrombocytopenic
purpura.13 Long-term prophylaxis with danazol has been started in
our casewith both improvement of clinical and biological course. No
drug- adverse effect has been recorded. Undesirable adverse effects
can be avoided by using the lowest effective drug dose and an
intermittent dosage regimen.
4. Conclusion
The main purpose of the management of HAE remains making
the correct diagnosis. Laryngeal oedema is the most common cause
of death related to HAE. It must be suspected and correctly
managed in any child presenting with severe respiratory distress.Long-term prophylaxis with danazol in childhood may reduce both
frequency and severity of HAE acute attacks.
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